Fulvestrant is used to treat hormone-receptor positive breast cancer in postmenopausal women whose disease has spread after treatment with an antiestrogen medicine.
Excerpts from the Fulvestrant (Faslodex) drug label:
Many breast cancers have estrogen receptors (ER) and the growth of these tumors can be stimulated by estrogen. Fulvestrant is an estrogen receptor antagonist that binds to the estrogen receptor in a competitive manner with affinity comparable to that of estradiol and downregulates the ER protein in human breast cancer cells.
Dose adjustment is not needed in patients co-prescribed CYP3A4 inhibitors or inducers.
For the complete drug label text with sections containing pharmacogenetic information highlighted, see the Fulvestrant drug label.
*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.